“Platform Technology”

01E.coli – based VLP Manufacturing Platform as an innovative solution against unmet and emerging viral infection

※ VLP : structurally resembling infectious virions, but non-infectious due to the lack the viral genome required for replication

02RIPT (RNA-Interaction mediated Protein manufacturing Technology)

High-yield & Fast VLP Manufacturing Platform Technology

03Strengths of E.coli-based VLP Vaccine

Conventional Viral Vaccine Manufacturing Process

Competitiveness of InThera VLP Vaccine

01. Virus Propagation

E.coli culture, instead of
mammalian cell culture

Increased facility efficiency and VLP manufacturing speed

04. Purification

High-level expression of capsid protein
Purification through simple &
convenient process

Improved unwanted effect due to high purity

05. Inactivation

No denaturation of antigen
due to the lack of
chemical inactivation process

Improved immunogenicity